Pembrolizumab-associated nephrotic syndrome recovered from transient hemodialysis in a patient with lung cancer

Ishibuchi, Kento; Iwakura, Takamasa; Kaneko, Mai; Fukasawa, Hirotaka; Furuya, Ryuichi

doi:10.1007/s13730-020-00462-0

Cited by 7 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We checked all titles and abstracts of the articles to identify pertinent articles, and then examined the contents of the remaining papers to determine their applicability to this investigation. survey identi ed 17 cases of ICI-related nephrotic syndrome, including our own (Table 1) [8][9][10][11][12][13][14][15][16][17][18][19][20]. The ratio of males (14) to females (3) was 4.7:1.…”

Section: Discussionmentioning

confidence: 99%

Nephrotic syndrome with acute kidney injury due to combination therapy of immune checkpoint inhibitors: A case report and review of the literature

Saiki,

Katayama,

Saiki

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Recent studies have focused on immune checkpoint inhibitors. Renal complications associated with the use of immune checkpoint inhibitors are uncommon compared with other immune-related adverse events. Acute interstitial nephritis accounts for most of these renal complications, with nephrotic syndrome quite rare. We herein report a case of nephrotic syndrome associated with immune checkpoint inhibitors that was more severe than that in previous cases. By comparing this case with previous reports, the possible reasons for the particular severity of this case are discussed.Case presentation A 75-year-old man developed nephrotic syndrome with acute kidney injury after the first combination therapy of nivolumab and ipilimumab for malignant pleural mesothelioma. The results of a kidney biopsy indicated minimal change disease with mild atherosclerosis and fusion of nearly all podocyte foot processes. Nivolumab and ipilimumab therapy were stopped, and treatment with corticosteroids was initiated. We investigated previously reported cases of nephrotic syndrome using immune checkpoint inhibitors. Seventeen cases of immune checkpoint inhibitor-related nephrotic syndrome, including ours, have been reported. Two of the 17 patients with immune checkpoint inhibitor-related nephrotic syndrome required hemodialysis treatment for acute kidney injury. Unlike many previously reported cases, the present patient was administered two different immune checkpoint inhibitors, which may be one of the reasons for the development of severe nephrotic syndrome.Conclusions In addition to previously reported risk factors, immune checkpoint inhibitor combination therapy can exacerbate nephrotic syndrome compared to immune checkpoint inhibitor monotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Nephrotic syndrome with acute kidney injury due to combination therapy of immune checkpoint inhibitors: A case report and review of the literature

Saiki,

Katayama,

Saiki

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…It is worth remembering the fact that ICI-induced AKI was described not only after the treatment with ipilimumab but after other ICIs as well. There were also reported cases of nephrotoxicities associated with pembrolizumab [ 52 , 75 , 76 ] and nivolumab [ 77 , 78 , 79 ].…”

Section: Immune Checkpoint Inhibitors (Icis)mentioning

confidence: 99%

Adverse Renal Effects of Anticancer Immunotherapy: A Review

Borówka

Łącki-Zynzeling

Nicze

et al. 2022

Cancers

View full text Add to dashboard Cite

Modern oncological therapy utilizes various types of immunotherapy. Immune checkpoint inhibitors (ICIs), chimeric antigen receptor T cells (CAR-T) therapy, cancer vaccines, tumor-targeting monoclonal antibodies (TT-mAbs), bispecific antibodies and cytokine therapy improve patients’ outcomes. However, stimulation of the immune system, beneficial in terms of fighting against cancer, generates the risk of harm to other cells in a patient’s body. Kidney damage belongs to the relatively rare adverse events (AEs). Best described, but still, superficially, are renal AEs in patients treated with ICIs. International guidelines issued by the European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO) cover the management of immune-related adverse events (irAEs) during ICI therapy. There are fewer data concerning real occurrence and possible presentations of renal adverse drug reactions of other immunotherapeutic methods. This implies the need for the collection of safety data during ongoing clinical trials and in the real-life world to characterize the hazard related to the use of new immunotherapies and management of irAEs.

show abstract

“…It is worth reminding the fact that ICI-induced AKI was described not only after the treatment with ipilimumab but after other ICIs as well. There were also reported cases of nephrotoxicities associated with pembrolizumab [52,76,77] and nivolumab [78][79][80].…”

Section: Occurrence and Specific Nephrotoxicitiesmentioning

confidence: 99%

Adverse Renal Effects of Anticancer Immunotherapy: A Review

Borówka¹,

Łącki-Zynzeling²,

Nicze³

et al. 2022

Preprint

View full text Add to dashboard Cite

Modern oncological therapy utilizes various types of immunotherapy. Immune checkpoint inhib-itors (ICIs), chimeric antigen receptor T cells (CAR-T) therapy, cancer vaccines and bispecific an-tibodies are improving patients’ outcomes. However, stimulation of the immune system, benefi-cial in terms of fighting against cancer, generates the risk of harm to other cells in a patient's body. Kidney damage belongs to the relatively rare adverse events (AEs). Best described, but still, su-perficially, are renal AEs in patients treated with ICIs. International guidelines issued by Euro-pean Society for Medical Oncology (ESMO) and American Society of Clinical Oncology (ASCO) cover the management of immune-related adverse events (irAEs) during ICI therapy. There are scarce data concerning renal adverse drug reactions of other immunotherapeutic methods. This implicates the need for the collection of safety data during ongoing clinical trials and in the re-al-life world to characterize the hazard related to the use of new immunotherapies and manage-ment of irAEs.

show abstract

Pembrolizumab-associated nephrotic syndrome recovered from transient hemodialysis in a patient with lung cancer

Cited by 7 publications

References 24 publications

Nephrotic syndrome with acute kidney injury due to combination therapy of immune checkpoint inhibitors: A case report and review of the literature

Nephrotic syndrome with acute kidney injury due to combination therapy of immune checkpoint inhibitors: A case report and review of the literature

Adverse Renal Effects of Anticancer Immunotherapy: A Review

Adverse Renal Effects of Anticancer Immunotherapy: A Review

Contact Info

Product

Resources

About